Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 44 Results

Title
Intervention Indication Therapeutic Area Year Actions
Rucaparib with nivolumab for the maintenance treatment of newly diagnosed epithelial ovarian, fallopian tube, or primary peritoneal cancer Nivolumab (Opdivo; BMS-936558; ONO-4538) , Rucaparib (Rubraca; PF-1367338) Breast cancer Breast Cancer 2022 View  |  Download
Relatlimab in combination with nivolumab for advanced melanoma – second line Nivolumab (Opdivo; BMS-936558; ONO-4538) , Relatlimab (BMS-986016; Anti-LAG-3) Melanoma Skin Cancer 2019 View  |  Download
Nivolumab with ipilimumab for previously untreated locally advanced non-small-cell lung cancer Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Nivolumab with ipilimumab adjuvant therapy for renal cell carcinoma Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Renal cell carcinoma (RCC) Renal Cancer 2022 View  |  Download
Nivolumab with docetaxel for advanced castration-resistant prostate cancer Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Prostate cancer Male Reproductive Cancer 2021 View  |  Download
Nivolumab with chemotherapy neoadjuvant followed by nivolumab adjuvant for treating early stage non-small-cell lung cancer Chemotherapy , Nivolumab (Opdivo; BMS-936558; ONO-4538) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Nivolumab in combination with rucaparib for metastatic castration-resistant prostate cancer with prior chemotherapy Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Enzalutamide (Xtandi; MDV3100) , Nivolumab (Opdivo; BMS-936558; ONO-4538) , Rucaparib (Rubraca; PF-1367338) Prostate cancer Male Reproductive Cancer 2019 View  |  Download
Nivolumab in combination with rucaparib for chemotherapy naive metastatic castration-resistant prostate cancer Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Enzalutamide (Xtandi; MDV3100) , Nivolumab (Opdivo; BMS-936558; ONO-4538) , Rucaparib (Rubraca; PF-1367338) Prostate cancer Male Reproductive Cancer 2019 View  |  Download
Nivolumab in combination with ipilimumab in addition to chemotherapy for treating non-small cell lung cancer – first line Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2018 View  |  Download
Nivolumab in combination with ipilimumab for the adjuvant treatment of melanoma Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Melanoma Skin Cancer 2019 View  |  Download
1 2 3 4 5
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications